BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36627205)

  • 21. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
    Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
    Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
    Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation.
    Choi JY; Lee S; Yun SM; Suh DH; Kim K; No JH; Jeong EH; Kim YB
    Nutr Cancer; 2018 Jan; 70(1):109-115. PubMed ID: 29111786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
    Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
    Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
    Guo YQ; Lu P; Duan ZF; Zhang Z
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):854-9. PubMed ID: 21211286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway.
    Yao X; Zhu F; Zhao Z; Liu C; Luo L; Yin Z
    J Cell Biochem; 2011 Oct; 112(10):2837-49. PubMed ID: 21608020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway.
    Rastelli EJ; Sannino S; Hart DJ; Sharlow ER; Lazo JS; Brodsky JL; Wipf P
    Bioorg Med Chem Lett; 2021 Aug; 46():128167. PubMed ID: 34089839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
    Liu CY; Tseng LM; Su JC; Chang KC; Chu PY; Tai WT; Shiau CW; Chen KF
    Breast Cancer Res; 2013; 15(4):R63. PubMed ID: 23938089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncostatin M promotes proliferation of ovarian cancer cells through signal transducer and activator of transcription 3.
    Li Q; Zhu J; Sun F; Liu L; Liu X; Yue Y
    Int J Mol Med; 2011 Jul; 28(1):101-8. PubMed ID: 21399864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
    Badache A; Hynes NE
    Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SH2 domain containing protein tyrosine phosphatase 2 regulates concanavalin A-dependent secretion and activation of matrix metalloproteinase 2 via the extracellular signal-regulated kinase and p38 pathways.
    Ruhul Amin AR; Oo ML; Senga T; Suzuki N; Feng GS; Hamaguchi M
    Cancer Res; 2003 Oct; 63(19):6334-9. PubMed ID: 14559821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiation-dependent prolactin responsiveness and stat (signal transducers and activators of transcription) signaling in rat ovarian cells.
    Russell DL; Richards JS
    Mol Endocrinol; 1999 Dec; 13(12):2049-64. PubMed ID: 10598581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo.
    Kandala PK; Srivastava SK
    Drug Discov Ther; 2012 Apr; 6(2):94-101. PubMed ID: 22622019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
    Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
    Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
    Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
    J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways.
    Teng R; Wang Y; Lv N; Zhang D; Williamson RA; Lei L; Chen P; Lei L; Wang B; Fu J; Liu X; He A; O'Dwyer M; Hu J
    J Immunol Res; 2020; 2020():4598476. PubMed ID: 33123602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
    Lofgren KA; Ostrander JH; Housa D; Hubbard GK; Locatelli A; Bliss RL; Schwertfeger KL; Lange CA
    Breast Cancer Res; 2011 Sep; 13(5):R89. PubMed ID: 21923922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A role for the extracellular signal-regulated kinase and p38 mitogen-activated protein kinases in interleukin-1 beta-stimulated delayed signal tranducer and activator of transcription 3 activation, atrial natriuretic factor expression, and cardiac myocyte morphology.
    Ng DC; Long CS; Bogoyevitch MA
    J Biol Chem; 2001 Aug; 276(31):29490-8. PubMed ID: 11382751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical therapeutic potential of a nitrosylating agent in the treatment of ovarian cancer.
    Giri S; Rattan R; Deshpande M; Maguire JL; Johnson Z; Graham RP; Shridhar V
    PLoS One; 2014; 9(6):e97897. PubMed ID: 24887420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.